Larkspur Biosciences is a biotechnology business that is developing the next generation of precision immunotherapies to combat cancer.
Larkspur Biosciences has raised $35.5M in total funding. The most recent round was Series A. The last funding was announced in May 2023.
Larkspur Biosciences's investors include Polaris Partners, 3E Bioventures, Takeda Ventures.
Larkspur Biosciences is headquartered in Watertown, United States.
Larkspur Biosciences is a biotechnology business that is developing the next generation of precision immunotherapies to combat cancer.
Larkspur Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Larkspur Biosciences — Funding & Investors." VCBacked, May 23, 2023, https://www.vcbacked.co/company/larkspur-biosciences. Accessed September 30, 2026.
VCBacked. (2023). Larkspur Biosciences — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/larkspur-biosciences
{{cite web |title=Larkspur Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/larkspur-biosciences |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated